CAR T-cell Therapy Market: Growth, Size, Share, and Trends

Report Code PH 9093
Published in Jul, 2024, By MarketsandMarkets™
Download PDF

Choose License Type

Buy Report Now Inquire Before Buying

CAR T-cell Therapy Market by Product (Abecma, Breyanzi, Carvykti, Yescarta, Tecartus, Kymriah), Target Antigen (CD19, BCMA), Indication (Multiple Myeloma, Leukemia, Lymphoma), Demographic (Adult, Pediatric), End User & Region - Global Forecast to 2029

Overview

The global CAR T-cell Therapy market, valued at US$3.7 billion in 2023, is forecasted to grow at a robust CAGR of 39.6%, reaching US$5.5 billion in 2024 and an impressive US$29.0 billion by 2029. The growth of this market due to the rise in investments and funding for CAR T-cell therapy developments and technological advancements in CAR T-cell therapy. The growing prevalence of cancer is also expected to support lucrative market growth. However, the high costs of CAR T-cell therapies and the adverse effects of the drugs are some of the factors likely to hamper the market growth.

CAR T-cell Therapy Market– Global Forecast and Key Opportunities to 2029

Attractive Opportunities in the CAR T-cell Therapy Market

ASIA PACIFIC:

Asia Pacific region is anticipated to grow at a significant CAGR during the forecast period. The region’s demographic trends and rising incidence of cancer and other diseases are expected to support market growth.

Increasing focus on CAR T-cell therapy pipeline is one of the major factors giving momentum to market growth.

The Asia Pacific market is projected to grow at a CAGR of 44.0% during the forecast period.

Technological advancements in the CAR T-cell therapy market are likely to create lucrative growth opportunities for the market players.

Adverse effects associated with CAR T-cell therapy is expected to pose a challenge to the growth of this market.

Global CAR T-cell Therapy Market Dynamics

Driver: Growing cancer prevalence

The growing prevalence of cancer is a prominent driver of market growth. According to the World Health Organization, in 2022, there were ~20 million new cancer cases and 9.7 million cancer-related deaths globally. An estimated 53.5 million individuals were living within five years of a cancer diagnosis. Statistically, about one-fifth of people will develop cancer in their lifetime, with approximately 1 in 9 men and 1 in 12 women succumbing to the disease. A projected surge of over 35 million new cancer cases is anticipated by 2050, reflecting a substantial 77% increase from the estimated 20 million cases recorded in 2022. Of these, Diffuse Large B-Cell Lymphoma (DLBCL) is the predominant form of Non-Hodgkin Lymphoma (NHL) in the US and globally, representing ~22% of newly identified cases of B-cell NHL in the US. Each year, over 18,000 individuals receive a diagnosis of DLBCL.

Restraint: High therapy costs

The high cost of CAR T-cell therapy represents a significant restraint on the market, posing challenges to widespread adoption and accessibility. One of the primary factors contributing to the elevated cost is the complex and individualized manufacturing process required for CAR T-cell therapies. Each treatment involves extracting T cells from the patient, genetically modifying them to express chimeric antigen receptors (CARs), and expanding these cells in a controlled laboratory environment before reinfusing them into the patient. This labor-intensive and time-consuming process incurs substantial costs, often exceeding USD 350,000 per treatment, as seen with therapies like KYMRIAH and Yescarta.

 

Opportunity: Expansion into solid tumors

Expansion into solid tumors represents a significant opportunity for the CAR T-cell therapy market, offering the potential for market growth and therapeutic advancements. Traditionally, CAR T-cell therapies have successfully treated hematologic malignancies such as B-cell lymphomas and Acute Lymphoblastic Leukemia (ALL). However, the application of CAR T-cell therapies to solid tumors has been limited due to unique challenges such as the hostile tumor microenvironment, heterogeneity, and physical barriers within solid tumors. Advances in this area can unlock new avenues for growth and innovation in the market.

Challenge: Patient recruitment for trials

Patient recruitment for clinical trials is a significant challenge in the CAR T-cell therapy market, posing obstacles to developing and approving new therapies. The complexity of CAR T-cell therapy trials, stringent eligibility criteria, and the rarity of target indications all contribute to the difficulty of enrolling sufficient patient numbers. One primary challenge is the stringent eligibility criteria for CAR T-cell trials. These criteria often include specific genetic markers, disease subtypes, and previous treatment histories, significantly narrowing the pool of eligible participants. Moreover, the geographic dispersion of patients with rare cancers adds complexity to patient recruitment. Rare conditions such as certain types of Acute Lymphoblastic Leukemia (ALL) or relapsed large B-cell Lymphoma have a limited patient base scattered across wide regions. This dispersion complicates the logistics of enrolling and managing patients in clinical trials.

Global CAR T-cell Therapy Market Ecosystem Analysis

The product CAR T-cell therapy segment of the Car T-Cell Therapy Manufacturing Industry commanded market share in 2023. Based on the products, the CAR T-cell therapy market is segmented into Abecma (idecabtagene vicleucel), Breyanzi (lisocabtagene maraleucel), Carvykti (ciltacabtagene autoleucel), Yescarta (axicabtagene ciloleucel), Tecartus (brexucabtagene autoleucel), Kymriah (tisagenlecleucel) and other products. The Yescarta segment accounted for the largest share of the CAR T-cell therapy market in 2023. The high share of this segment is mainly attributed to the early entry into the market allowing Gilead Sciences, Inc. to gain significant experience in commercialization and market dynamics and establish a strong brand presence. Additionally, advancements in Yescarta is further likely to drive segmental growth. For example, Gilead Sciences, Inc. received U.S. FDA approval for a change in the manufacturing process for Yescarta which would result in reduced median turnaround time from leukapheresis to product release from 16 Days to 14 Days.

CAR T-cell Therapy Market Ecosystem

The CD19 target antigen segment of the CAR T-cell therapy industry is poised to exhibit substantial growth at a significant CAGR throughout the forecast period.

Based on targets, the CAR T-cell therapy market is classified into segmented into BCMA, CD19 and other targets. In 2023, the CD19 targets segment accounted for the highest share of the global CAR T-cell therapy market. The large share of this segment is due to the to the growing prevalence of cancers such as B-cell Lymphomas which express CD19 antigen on the cell surface.

Asia Pacific Region Holds the Largest Share of the CAR T-cell Therapy Market

There are five main regional segmentations for the CAR T-cell therapy market—North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. In 2023, North America held dominant share in CAR T-cell therapy market. Early adoption & regulatory framework, significant investment in research and development and advanced healthcare infrastructure are some of the factors uplifting the market growth in the region. Asia Pacific is anticipated to grow at significant CAGR during the forecast period of 2024-2029. Increasing healthcare investments, rising cancer incidence, rich CAR T-cell therapy pipeline development, and supportive regulatory frameworks are likely to drive the growth of the CAR T-cell therapy market in the region.

 
 
CAR T-cell Therapy Market Region

Recent Developments of CAR T-Cell Therapy Market

  • In May 2024, The US FDA granted accelerated approval to BREYANZI (lisocabtagene maraleucel) for the treatment of adult patients with relapsed or refractory Follicular Lymphoma (FL) who have received two or more prior lines of systemic therapy. In April 2024, Bristol entered into a worldwide capacity reservation and supply agreement with Cellares to manufacture CAR T-cell therapies using Cellares’s automated & high-throughput manufacturing platform called Cell Shuttle.
  • In January 2023, Gilead received approval from the US FDA for a change in manufacturing processes for YESCARTA (axicabtagene ciloleucel) to reduce the median turnaround time (TAT) in the US to 14 days from 16 days.

Key Market Players

KEY PLAYERS IN THE CAR T-CELL THERAPY MARKET INCLUDE

Want to explore hidden markets that can drive new revenue in CAR T-cell Therapy Market?

Scope of the Report

Report Attribute Details
Market Revenue in 2024 $5.5 billion
Projected Revenue by 2029 $29.0 billion
Revenue Rate Poised to Grow at a CAGR of 39.6%
Market Driver Growing cancer prevalence
Market Opportunity Expansion into solid tumors

 

Key Questions Addressed by the Report

What is the expected growth rate of the CAR T-cell therapy market between 2024 and 2029?
The global CAR T-cell therapy market is projected to grow from USD 5.5 billion in 2024 to USD 29.0 billion by 2029, demonstrating a robust CAGR of 39.6%.
What factors are driving the growth of the CAR T-cell therapy market?
The CAR T-cell therapy market is driven by the rising prevalence of cancer, increasing investments and funding in CAR T-cell therapy research, and the development of advanced CAR T-cell therapies.
What are the major challenges in the CAR T-cell therapy market?
Challenges in the CAR T-cell therapy market include high therapy costs and difficulties in patient recruitment for clinical trials, particularly for rare cancers and target indications.
Which product held the largest share of the CAR T-cell therapy market in 2023?
Yescarta (axicabtagene ciloleucel) accounted for the largest share of the CAR T-cell therapy market in 2023, driven by its early market entry and advancements in the manufacturing process that reduced turnaround times.
What is the key opportunity for the CAR T-cell therapy market?
The expansion of CAR T-cell therapies into solid tumors presents a significant opportunity for market growth, potentially unlocking new applications and driving therapeutic advancements in the field.
Which region is expected to exhibit the highest growth in the CAR T-cell therapy market?
The Asia Pacific region is projected to exhibit the highest CAGR during the forecast period of 2024–2029, driven by rising healthcare investments, increasing cancer incidence, and a growing CAR T-cell therapy pipeline.
How does the high cost of CAR T-cell therapy impact market adoption?
The high cost of CAR T-cell therapy, often exceeding USD 350,000 per treatment, limits its widespread adoption and accessibility, posing a significant challenge to market growth.
What are the key targets for CAR T-cell therapies?
The key targets for CAR T-cell therapies include BCMA and CD19, with the CD19 target segment holding the largest market share due to its association with cancers such as B-cell Lymphomas.
What is the role of technological advancements in the CAR T-cell therapy market?
Technological advancements in CAR T-cell therapy, such as improvements in the manufacturing process and developments in targeting solid tumors, are expected to significantly drive market growth and innovation.
What are the recent developments in the CAR T-cell therapy market?
Recent developments include the US FDA granting accelerated approval for BREYANZI for relapsed or refractory Follicular Lymphoma and Gilead Sciences' improvements in Yescarta's manufacturing process.

 

Personalize This Research

  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
Request A Free Customisation

Let Us Help You

  • What are the Known and Unknown Adjacencies Impacting the CAR T-cell Therapy Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
Customized Workshop Request

Table Of Contents

Exclusive indicates content/data unique to MarketsandMarkets and not available with any competitors.

TITLE
PAGE NO
INTRODUCTION
25
RESEARCH METHODOLOGY
29
EXECUTIVE SUMMARY
42
PREMIUM INSIGHTS
46
MARKET OVERVIEW
49
  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    DRIVERS
    - Growing cancer prevalence
    - Technological advancements in CAR T-cell therapies
    - Rising investment and funding for therapy development
    RESTRAINTS
    - High therapy costs
    - Adverse effects
    OPPORTUNITIES
    - Expansion into solid tumors
    - Collaborations and partnerships
    CHALLENGES
    - Patient recruitment for trials
    - Reimbursement issues
  • 5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
  • 5.4 VALUE CHAIN ANALYSIS
  • 5.5 ECOSYSTEM ANALYSIS
    PRODUCTS
    END USERS
    REGULATORY BODIES
  • 5.6 TECHNOLOGY ANALYSIS
    KEY TECHNOLOGIES
    - CAR DESIGN AND OPTIMIZATION
    - VIRAL VECTOR TECHNOLOGY
    - CELL CULTURE AND EXPANSION TECHNIQUES
    COMPLIMENTARY TECHNOLOGIES
    - GENE EDITING TECHNOLOGY (CRISPR-CAS9-BASED GENOME EDITING)
    ADJACENT TECHNOLOGIES
    - MONITORING AND IMAGING TECHNOLOGIES
  • 5.7 PATENT ANALYSIS
    METHODOLOGY
    NUMBER OF PATENTS FILED
    INNOVATION AND PATENT APPLICATIONS
    TOP APPLICANTS
  • 5.8 PRICING ANALYSIS
    AVERAGE SELLING PRICE, BY TYPE
    AVERAGE SELLING PRICE, BY REGION
    AVERAGE SELLING PRICE TREND, BY PRODUCT
  • 5.9 KEY CONFERENCES & EVENTS, 2024–2O25
  • 5.10 REGULATORY LANDSCAPE
    REGULATORY SCENARIO
    REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 5.11 INVESTMENT & FUNDING SCENARIO
  • 5.12 PORTER’S FIVE FORCES ANALYSIS
    INTENSITY OF COMPETITIVE RIVALRY
    BARGAINING POWER OF SUPPLIERS
    BARGAINING POWER OF BUYERS
    THREAT OF SUBSTITUTES
    THREAT OF NEW ENTRANTS
  • 5.13 KEY STAKEHOLDERS & BUYING CRITERIA
    KEY BUYING CRITERIA
CAR T-CELL THERAPY MARKET, BY PRODUCT
86
  • 6.1 INTRODUCTION
  • 6.2 YESCARTA
    INCREASING REACH TO DRIVE MARKET
  • 6.3 KYMRIAH
    APPROVAL FOR PEDIATRIC USE TO SUPPORT MARKET GROWTH
  • 6.4 CARVYKTI
    WIDESPREAD REACH TO ENSURE MARKET GROWTH
  • 6.5 ABECMA
    RISING RESEARCH FOR ALTERNATIVE INDICATIONS TO DRIVE MARKET
  • 6.6 TECARTUS
    GROWING FOCUS ON PATIENT-CENTRIC REIMBURSEMENT TO PROPEL MARKET
  • 6.7 BREYANZI
    MULTIPLE INDICATIONS TO PROPEL MARKET GROWTH
  • 6.8 OTHER PRODUCTS
CAR T-CELL THERAPY MARKET, BY TARGET
106
  • 7.1 INTRODUCTION
  • 7.2 CD19
    RISING INDICATIONS IN PIPELINE TO DRIVE MARKET
  • 7.3 BCMA
    TECHNOLOGICAL ADVANCEMENTS IN CAR T-CELL THERAPY TO PROPEL MARKET GROWTH
  • 7.4 OTHER TARGETS
CAR T-CELL THERAPY MARKET, BY INDICATION
117
  • 8.1 INTRODUCTION
  • 8.2 MULTIPLE MYELOMA
    RISING INCIDENCE OF MULTIPLE MYELOMA TO DRIVE MARKET
  • 8.3 B-CELL LYMPHOMA
    RISING PREVALENCE TO PROPEL MARKET GROWTH
  • 8.4 ACUTE LYMPHOBLASTIC LEUKEMIA
    FOCUS ON AFFORDABLE CAR T-CELL THERAPIES TO DRIVE MARKET
  • 8.5 OTHER INDICATIONS
CAR T-CELL THERAPY MARKET, BY DEMOGRAPHIC
130
  • 9.1 INTRODUCTION
  • 9.2 ADULTS
    INCREASING NUMBER OF LYMPHOMAS TO DRIVE MARKET
  • 9.3 PEDIATRICS
    RISING PREVALENCE OF TARGET DISEASES TO PROPEL MARKET GROWTH
CAR T-CELL THERAPY MARKET, BY END USER
137
  • 10.1 INTRODUCTION
  • 10.2 HOSPITALS
    GROWING PREVALENCE OF CANCER TO DRIVE MARKET
  • 10.3 SPECIALTY CENTERS
    GROWING RESEARCH COLLABORATIONS TO PROPEL MARKET
  • 10.4 LONG-TERM CARE FACILITIES
    GROWING CASES OF CHRONIC DISORDERS TO DRIVE MARKET
CAR T-CELL THERAPY MARKET, BY REGION
146
  • 11.1 INTRODUCTION
  • 11.2 NORTH AMERICA
    NORTH AMERICA: RECESSION IMPACT
    US
    - Rising R&D activities for CAR T-cell therapies to drive market
    CANADA
    - Government initiatives for regenerative medicine research to drive market
  • 11.3 EUROPE
    EUROPE: RECESSION IMPACT
    GERMANY
    - Rising focus on clinical research to drive market
    UK
    - Rising technological advancements in automation to drive market
    FRANCE
    - Growing focus on cell & gene therapy initiatives to boost demand
    ITALY
    - Growth in biotech sector to drive market
    SPAIN
    - Rising focus on cell therapies to support market growth
    REST OF EUROPE
  • 11.4 ASIA PACIFIC
    ASIA PACIFIC: RECESSION IMPACT
    CHINA
    - Rising number of CAR T-cell clinical trials to support market growth
    JAPAN
    - Increasing product approvals to drive market
    INDIA
    - Rising incidence of cancer and growing focus on product commercialization to boost demand
    AUSTRALIA
    - Robust infrastructure for clinical trials and well-developed healthcare sector to drive market
    SOUTH KOREA
    - Rising growth in biopharmaceutical industry to drive market
    REST OF ASIA PACIFIC
  • 11.5 LATIN AMERICA
    LATIN AMERICA: RECESSION IMPACT
    BRAZIL
    - High expenditure on healthcare to support market growth
    REST OF LATIN AMERICA
  • 11.6 MIDDLE EAST & AFRICA
    MEA TO GROW AT SLOWER PACE DURING FORECAST PERIOD
    MIDDLE EAST & AFRICA: RECESSION IMPACT
COMPETITIVE LANDSCAPE
204
  • 12.1 OVERVIEW
  • 12.2 KEY PLAYER STRATEGY/RIGHT TO WIN
    OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN CAR T-CELL THERAPY MARKET
  • 12.3 REVENUE ANALYSIS
  • 12.4 MARKET SHARE ANALYSIS
    RANKING OF KEY MARKET PLAYERS
  • 12.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
    STARS
    EMERGING LEADERS
    PERVASIVE PLAYERS
    PARTICIPANTS
    COMPANY FOOTPRINT: KEY PLAYERS, 2023
    - Company footprint
    - Product footprint
    - Target footprint
    - Indication footprint
    - Region footprint
  • 12.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
    PROGRESSIVE COMPANIES
    RESPONSIVE COMPANIES
    DYNAMIC COMPANIES
    STARTING BLOCKS
    COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
  • 12.7 VALUATION & FINANCIAL METRICS
    FINANCIAL METRICS
    COMPANY VALUATION
  • 12.8 BRAND/PRODUCT COMPARISON
  • 12.9 COMPETITIVE SCENARIO
    PRODUCT LAUNCHES & APPROVALS
    DEALS
    EXPANSIONS
    OTHER DEVELOPMENTS
COMPANY PROFILES
221
  • 13.1 KEY PLAYERS
    BRISTOL-MYERS SQUIBB COMPANY
    - Business overview
    - Products offered
    - Recent developments
    - MnM view
    GILEAD SCIENCES, INC.
    - Business overview
    - Products offered
    - Recent developments
    - MnM view
    NOVARTIS AG
    - Business overview
    - Products offered
    - Recent developments
    - MnM view
    JOHNSON & JOHNSON
    - Business overview
    - Products offered
    - Recent developments
    JW (CAYMAN) THERAPEUTICS CO. LTD.
    - Business overview
    - Products offered
    - Recent developments
    IMMUNOADOPTIVE CELL THERAPY PRIVATE LIMITED (IMMUNOACT)
    - Business overview
    - Products offered
    - Recent developments
    CARSGEN THERAPEUTICS HOLDINGS LIMITED
    - Business overview
    - Products offered
    - Recent developments
    IASO BIOTHERAPEUTICS
    - Business overview
    - Products offered
    - Recent developments
  • 13.2 OTHER PLAYERS
    GUANGZHOU BIO-GENE TECHNOLOGY CO., LTD (HEDY GROUP CO., LTD.)
    CARTESIAN THERAPEUTICS, INC.
    AUTOLUS THERAPEUTICS
    ALLOGENE THERAPEUTICS
    CRISPR THERAPEUTICS
    WUGEN
APPENDIX
258
  • 14.1 DISCUSSION GUIDE
  • 14.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
  • 14.3 CUSTOMIZATION OPTIONS
  • 14.4 RELATED REPORTS
  • 14.5 AUTHOR DETAILS
LIST OF TABLES
 
  • TABLE 1 IMPACT ANALYSIS OF SUPPLY-SIDE AND DEMAND-SIDE FACTORS
  • TABLE 2 GLOBAL INFLATION RATE PROJECTIONS, 2023–2029 (% GROWTH)
  • TABLE 3 ADVERSE EFFECTS ASSOCIATED WITH CAR T-CELL THERAPY
  • TABLE 4 KEY PRODUCT PROVIDERS IN CAR T-CELL THERAPY MARKET
  • TABLE 5 KEY END USERS IN CAR T-CELL THERAPY MARKET
  • TABLE 6 KEY REGULATORY BODIES IN CAR T-CELL THERAPY MARKET
  • TABLE 7 NUMBER OF PATENTS FILED IN CAR T-CELL THERAPY MARKET, BY DOCUMENT TYPE, 2014–2024
  • TABLE 8 TOP 12 PATENT OWNERS IN CAR T-CELL THERAPY MARKET, 2014–2024
  • TABLE 9 DETAILED ANALYSIS OF KEY PATENTS IN CAR T-CELL THERAPY MARKET
  • TABLE 10 AVERAGE SELLING PRICE FOR LEADING CAR T-CELL THERAPEUTIC DRUGS
  • TABLE 11 AVERAGE SELLING PRICE FOR MAJOR CAR T-CELL THERAPEUTIC DRUGS, BY REGION
  • TABLE 12 INDICATIVE PRICING ANALYSIS FOR CAR T-CELL THERAPY, BY PRODUCT, 2021–2023
  • TABLE 13 KEY CONFERENCES & EVENTS, JUNE 2024–DECEMBER 2025
  • TABLE 14 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 15 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 16 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 17 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 18 MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 19 CAR T-CELL THERAPY MARKET: PORTER’S FIVE FORCES ANALYSIS
  • TABLE 20 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS
  • TABLE 21 KEY BUYING CRITERIA FOR PRODUCTS
  • TABLE 22 CAR T-CELL THERAPY MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • TABLE 23 CAR T-CELL THERAPY MARKET, BY PRODUCT, 2022–2029 (UNITS)
  • TABLE 24 YESCARTA MARKET, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 25 NORTH AMERICA: YESCARTA MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 26 EUROPE: YESCARTA MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 27 ASIA PACIFIC: YESCARTA MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 28 LATIN AMERICA: YESCARTA MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 29 KYMRIAH MARKET, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 30 NORTH AMERICA: KYMRIAH MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 31 EUROPE: KYMRIAH MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 32 ASIA PACIFIC: KYMRIAH MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 33 LATIN AMERICA: KYMRIAH MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 34 CARVYKTI MARKET, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 35 NORTH AMERICA: CARVYKTI MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 36 EUROPE: CARVYKTI MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 37 ASIA PACIFIC: CARVYKTI MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 38 LATIN AMERICA: CARVYKTI MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 39 ABECMA MARKET, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 40 NORTH AMERICA: ABECMA MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 41 EUROPE: ABECMA MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 42 ASIA PACIFIC: ABECMA MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 43 LATIN AMERICA: ABECMA MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 44 TECARTUS MARKET, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 45 NORTH AMERICA: TECARTUS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 46 EUROPE: TECARTUS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 47 ASIA PACIFIC: TECARTUS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 48 LATIN AMERICA: TECARTUS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 49 BREYANZI MARKET, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 50 NORTH AMERICA: BREYANZI MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 51 EUROPE: BREYANZI MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 52 ASIA PACIFIC: BREYANZI MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 53 LATIN AMERICA: BREYANZI MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 54 OTHER CAR T-CELL THERAPY PRODUCTS MARKET, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 55 NORTH AMERICA: OTHER CAR T-CELL THERAPY PRODUCTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 56 EUROPE: OTHER CAR T-CELL THERAPY PRODUCTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 57 ASIA PACIFIC: OTHER CAR T-CELL THERAPY PRODUCTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 58 LATIN AMERICA: OTHER CAR T-CELL THERAPY PRODUCTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 59 CAR T-CELL THERAPY MARKET, BY TARGET, 2022–2029 (USD MILLION)
  • TABLE 60 COMMERCIALLY AVAILABLE CD19 ANTIGEN-TARGETING CAR T-CELL THERAPIES
  • TABLE 61 CD19-TARGETING CAR T-CELL THERAPY MARKET, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 62 NORTH AMERICA: CD19-TARGETING CAR T-CELL THERAPY MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 63 EUROPE: CD19-TARGETING CAR T-CELL THERAPY MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 64 ASIA PACIFIC: CD19-TARGETING CAR T-CELL THERAPY MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 65 LATIN AMERICA: CD19-TARGETING CAR T-CELL THERAPY MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 66 COMMERCIALLY AVAILABLE BCMA ANTIGEN-TARGETING CAR T-CELL THERAPIES
  • TABLE 67 BCMA-TARGETING CAR T-CELL THERAPY MARKET, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 68 NORTH AMERICA: BCMA-TARGETING CAR T-CELL THERAPY MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 69 EUROPE: BCMA-TARGETING CAR T-CELL THERAPY MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 70 ASIA PACIFIC: BCMA-TARGETING CAR T-CELL THERAPY MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 71 LATIN AMERICA: BCMA-TARGETING CAR T-CELL THERAPY MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 72 OTHER CAR T-CELL THERAPY TARGETS MARKET, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 73 NORTH AMERICA: OTHER CAR T-CELL THERAPY TARGETS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 74 EUROPE: OTHER CAR T-CELL THERAPY TARGETS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 75 ASIA PACIFIC: OTHER CAR T-CELL THERAPY TARGETS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 76 LATIN AMERICA: OTHER CAR T-CELL THERAPY TARGETS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 77 CAR T-CELL THERAPY MARKET, BY INDICATION, 2022–2029 (USD MILLION)
  • TABLE 78 MULTIPLE MYELOMA, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 79 NORTH AMERICA: MULTIPLE MYELOMA MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 80 EUROPE: MULTIPLE MYELOMA MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 81 ASIA PACIFIC: MULTIPLE MYELOMA MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 82 LATIN AMERICA: MULTIPLE MYELOMA MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 83 CAR T-CELL THERAPY MARKET FOR B-CELL LYMPHOMA, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 84 NORTH AMERICA: CAR T-CELL THERAPY MARKET FOR B-CELL LYMPHOMA, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 85 EUROPE: CAR T-CELL THERAPY MARKET FOR B-CELL LYMPHOMA, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 86 ASIA PACIFIC: CAR T-CELL THERAPY MARKET FOR B-CELL LYMPHOMA, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 87 LATIN AMERICA: CAR T-CELL THERAPY MARKET FOR B-CELL LYMPHOMA, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 88 CAR T-CELL THERAPY MARKET FOR ACUTE LYMPHOBLASTIC LEUKEMIA, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 89 NORTH AMERICA: CAR T-CELL THERAPY MARKET FOR ACUTE LYMPHOBLASTIC LEUKEMIA, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 90 EUROPE: CAR T-CELL THERAPY MARKET FOR ACUTE LYMPHOBLASTIC LEUKEMIA, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 91 ASIA PACIFIC: CAR T-CELL THERAPY MARKET FOR ACUTE LYMPHOBLASTIC LEUKEMIA, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 92 LATIN AMERICA: CAR T-CELL THERAPY MARKET FOR ACUTE LYMPHOBLASTIC LEUKEMIA, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 93 CAR T-CELL THERAPY MARKET FOR OTHER INDICATIONS, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 94 NORTH AMERICA: CAR T-CELL THERAPY MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 95 EUROPE: CAR T-CELL THERAPY MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 96 ASIA PACIFIC: CAR T-CELL THERAPY MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 97 LATIN AMERICA: CAR T-CELL THERAPY MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 98 CAR T-CELL THERAPY MARKET, BY DEMOGRAPHIC, 2022–2029 (USD MILLION)
  • TABLE 99 CAR T-CELL THERAPY MARKET FOR ADULTS, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 100 NORTH AMERICA: CAR T-CELL THERAPY MARKET FOR ADULTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 101 EUROPE: CAR T-CELL THERAPY MARKET FOR ADULTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 102 ASIA PACIFIC: CAR T-CELL THERAPY MARKET FOR ADULTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 103 LATIN AMERICA: CAR T-CELL THERAPY MARKET FOR ADULTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 104 CAR T-CELL THERAPY MARKET FOR PEDIATRICS, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 105 NORTH AMERICA: CAR T-CELL THERAPY MARKET FOR PEDIATRICS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 106 EUROPE: CAR T-CELL THERAPY MARKET FOR PEDIATRICS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 107 ASIA PACIFIC: CAR T-CELL THERAPY MARKET FOR PEDIATRICS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 108 LATIN AMERICA: CAR T-CELL THERAPY MARKET FOR PEDIATRICS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 109 CAR T-CELL THERAPY MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 110 CAR T-CELL THERAPY MARKET FOR HOSPITALS, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 111 NORTH AMERICA: CAR T-CELL THERAPY MARKET FOR HOSPITALS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 112 EUROPE: CAR T-CELL THERAPY MARKET FOR HOSPITALS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 113 ASIA PACIFIC: CAR T-CELL THERAPY MARKET FOR HOSPITALS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 114 LATIN AMERICA: CAR T-CELL THERAPY MARKET FOR HOSPITALS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 115 CAR T-CELL THERAPY MARKET FOR SPECIALTY CENTERS, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 116 NORTH AMERICA: CAR T-CELL THERAPY MARKET FOR SPECIALTY CENTERS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 117 EUROPE: CAR T-CELL THERAPY MARKET FOR SPECIALTY CENTERS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 118 ASIA PACIFIC: CAR T-CELL THERAPY MARKET FOR SPECIALTY CENTERS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 119 LATIN AMERICA: CAR T-CELL THERAPY MARKET FOR SPECIALTY CENTERS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 120 CAR T-CELL THERAPY MARKET FOR LONG-TERM CARE FACILITIES, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 121 NORTH AMERICA: CAR T-CELL THERAPY MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 122 EUROPE: CAR T-CELL THERAPY MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 123 ASIA PACIFIC: CAR T-CELL THERAPY MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 124 LATIN AMERICA: CAR T-CELL THERAPY MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 125 CAR T-CELL THERAPY MARKET, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 126 NORTH AMERICA: CAR T-CELL THERAPY MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 127 NORTH AMERICA: CAR T-CELL THERAPY MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • TABLE 128 NORTH AMERICA: CAR T-CELL THERAPY MARKET, BY TARGET, 2022–2029 (USD MILLION)
  • TABLE 129 NORTH AMERICA: CAR T-CELL THERAPY MARKET, BY INDICATION, 2022–2029 (USD MILLION)
  • TABLE 130 NORTH AMERICA: CAR T-CELL THERAPY MARKET, BY DEMOGRAPHIC, 2022–2029 (USD MILLION)
  • TABLE 131 NORTH AMERICA: CAR T-CELL THERAPY MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 132 US: CAR T-CELL THERAPY MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • TABLE 133 US: CAR T-CELL THERAPY MARKET, BY TARGET, 2022–2029 (USD MILLION)
  • TABLE 134 US: CAR T-CELL THERAPY MARKET, BY INDICATION, 2022–2029 (USD MILLION)
  • TABLE 135 US: CAR T-CELL THERAPY MARKET, BY DEMOGRAPHIC, 2022–2029 (USD MILLION)
  • TABLE 136 US: CAR T-CELL THERAPY MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 137 CANADA: CAR T-CELL THERAPY MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • TABLE 138 CANADA: CAR T-CELL THERAPY MARKET, BY TARGET, 2022–2029 (USD MILLION)
  • TABLE 139 CANADA: CAR T-CELL THERAPY MARKET, BY INDICATION, 2 022–2029 (USD MILLION)
  • TABLE 140 CANADA: CAR T-CELL THERAPY MARKET, BY DEMOGRAPHIC, 2022–2029 (USD MILLION)
  • TABLE 141 CANADA: CAR T-CELL THERAPY MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 142 EUROPE: CAR T-CELL THERAPY MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 143 EUROPE: CAR T-CELL THERAPY MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • TABLE 144 EUROPE: CAR T-CELL THERAPY MARKET, BY TARGET, 2022–2029 (USD MILLION)
  • TABLE 145 EUROPE: CAR T-CELL THERAPY MARKET, BY INDICATION, 2 022–2029 (USD MILLION)
  • TABLE 146 EUROPE: CAR T-CELL THERAPY MARKET, BY DEMOGRAPHIC, 2022–2029 (USD MILLION)
  • TABLE 147 EUROPE: CAR T-CELL THERAPY MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 148 GERMANY: CAR T-CELL THERAPY MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • TABLE 149 GERMANY: CAR T-CELL THERAPY MARKET, BY TARGET, 2022–2029 (USD MILLION)
  • TABLE 150 GERMANY: CAR T-CELL THERAPY MARKET, BY INDICATION, 2022–2029 (USD MILLION)
  • TABLE 151 GERMANY: CAR T-CELL THERAPY MARKET, BY DEMOGRAPHIC, 2022–2029 (USD MILLION)
  • TABLE 152 GERMANY: CAR T-CELL THERAPY MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 153 UK: CAR T-CELL THERAPY MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • TABLE 154 UK: CAR T-CELL THERAPY MARKET, BY TARGET, 2022–2029 (USD MILLION)
  • TABLE 155 UK: CAR T-CELL THERAPY MARKET, BY INDICATION, 2022–2029 (USD MILLION)
  • TABLE 156 UK: CAR T-CELL THERAPY MARKET, BY DEMOGRAPHIC, 2022–2029 (USD MILLION)
  • TABLE 157 UK: CAR T-CELL THERAPY MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 158 FRANCE: CAR T-CELL THERAPY MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • TABLE 159 FRANCE: CAR T-CELL THERAPY MARKET, BY TARGET, 2022–2029 (USD MILLION)
  • TABLE 160 FRANCE: CAR T-CELL THERAPY MARKET, BY INDICATION, 2022–2029 (USD MILLION)
  • TABLE 161 FRANCE: CAR T-CELL THERAPY MARKET, BY DEMOGRAPHIC, 2022–2029 (USD MILLION)
  • TABLE 162 FRANCE: CAR T-CELL THERAPY MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 163 ITALY: CAR T-CELL THERAPY MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • TABLE 164 ITALY: CAR T-CELL THERAPY MARKET, BY TARGET, 2022–2029 (USD MILLION)
  • TABLE 165 ITALY: CAR T-CELL THERAPY MARKET, BY INDICATION, 2022–2029 (USD MILLION)
  • TABLE 166 ITALY: CAR T-CELL THERAPY MARKET, BY DEMOGRAPHIC, 2022–2029 (USD MILLION)
  • TABLE 167 ITALY: CAR T-CELL THERAPY MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 168 SPAIN: CAR T-CELL THERAPY MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • TABLE 169 SPAIN: CAR T-CELL THERAPY MARKET, BY TARGET, 2022–2029 (USD MILLION)
  • TABLE 170 SPAIN: CAR T-CELL THERAPY MARKET, BY INDICATION, 2022–2029 (USD MILLION)
  • TABLE 171 SPAIN: CAR T-CELL THERAPY MARKET, BY DEMOGRAPHIC, 2022–2029 (USD MILLION)
  • TABLE 172 SPAIN: CAR T-CELL THERAPY MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 173 REST OF EUROPE: CAR T-CELL THERAPY MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • TABLE 174 REST OF EUROPE: CAR T-CELL THERAPY MARKET, BY TARGET, 2022–2029 (USD MILLION)
  • TABLE 175 REST OF EUROPE: CAR T-CELL THERAPY MARKET, BY INDICATION, 2022–2029 (USD MILLION)
  • TABLE 176 REST OF EUROPE: CAR T-CELL THERAPY MARKET, BY DEMOGRAPHIC, 2022–2029 (USD MILLION)
  • TABLE 177 REST OF EUROPE: CAR T-CELL THERAPY MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 178 ASIA PACIFIC: CAR T-CELL THERAPY MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 179 ASIA PACIFIC: CAR T-CELL THERAPY MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • TABLE 180 ASIA PACIFIC: CAR T-CELL THERAPY MARKET, BY TARGET, 2022–2029 (USD MILLION)
  • TABLE 181 ASIA PACIFIC: CAR T-CELL THERAPY MARKET, BY INDICATION, 2022–2029 (USD MILLION)
  • TABLE 182 ASIA PACIFIC: CAR T-CELL THERAPY MARKET, BY DEMOGRAPHIC, 2022–2029 (USD MILLION)
  • TABLE 183 ASIA PACIFIC: CAR T-CELL THERAPY MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 184 CHINA: CAR T-CELL THERAPY MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • TABLE 185 CHINA: CAR T-CELL THERAPY MARKET, BY TARGET, 2022–2029 (USD MILLION)
  • TABLE 186 CHINA: CAR T-CELL THERAPY MARKET, BY INDICATION, 2022–2029 (USD MILLION)
  • TABLE 187 CHINA: CAR T-CELL THERAPY MARKET, BY DEMOGRAPHIC, 2022–2029 (USD MILLION)
  • TABLE 188 CHINA: CAR T-CELL THERAPY MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 189 JAPAN: CAR T-CELL THERAPY MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • TABLE 190 JAPAN: CAR T-CELL THERAPY MARKET, BY TARGET, 2022–2029 (USD MILLION)
  • TABLE 191 JAPAN: CAR T-CELL THERAPY MARKET, BY INDICATION, 2022–2029 (USD MILLION)
  • TABLE 192 JAPAN: CAR T-CELL THERAPY MARKET, BY DEMOGRAPHIC, 2022–2029 (USD MILLION)
  • TABLE 193 JAPAN: CAR T-CELL THERAPY MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 194 INDIA: CAR T-CELL THERAPY MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • TABLE 195 INDIA: CAR T-CELL THERAPY MARKET, BY TARGET, 2022–2029 (USD MILLION)
  • TABLE 196 INDIA: CAR T-CELL THERAPY MARKET, BY INDICATION, 2022–2029 (USD MILLION)
  • TABLE 197 INDIA: CAR T-CELL THERAPY MARKET, BY DEMOGRAPHIC, 2022–2029 (USD MILLION)
  • TABLE 198 INDIA: CAR T-CELL THERAPY MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 199 AUSTRALIA: CAR T-CELL THERAPY MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • TABLE 200 AUSTRALIA: CAR T-CELL THERAPY MARKET, BY TARGET, 2022–2029 (USD MILLION)
  • TABLE 201 AUSTRALIA: CAR T-CELL THERAPY MARKET, BY INDICATION, 2022–2029 (USD MILLION)
  • TABLE 202 AUSTRALIA: CAR T-CELL THERAPY MARKET, BY DEMOGRAPHIC, 2022–2029 (USD MILLION)
  • TABLE 203 AUSTRALIA: CAR T-CELL THERAPY MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 204 SOUTH KOREA: CAR T-CELL THERAPY MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • TABLE 205 SOUTH KOREA: CAR T-CELL THERAPY MARKET, BY TARGET, 2022–2029 (USD MILLION)
  • TABLE 206 SOUTH KOREA: CAR T-CELL THERAPY MARKET, BY INDICATION, 2022–2029 (USD MILLION)
  • TABLE 207 SOUTH KOREA: CAR T-CELL THERAPY MARKET, BY DEMOGRAPHIC, 2022–2029 (USD MILLION)
  • TABLE 208 SOUTH KOREA: CAR T-CELL THERAPY MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 209 REST OF ASIA PACIFIC: CAR T-CELL THERAPY MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • TABLE 210 REST OF ASIA PACIFIC: CAR T-CELL THERAPY MARKET, BY TARGET, 2022–2029 (USD MILLION)
  • TABLE 211 REST OF ASIA PACIFIC: CAR T-CELL THERAPY MARKET, BY INDICATION, 2022–2029 (USD MILLION)
  • TABLE 212 REST OF ASIA PACIFIC: CAR T-CELL THERAPY MARKET, BY DEMOGRAPHIC, 2022–2029 (USD MILLION)
  • TABLE 213 REST OF ASIA PACIFIC: CAR T-CELL THERAPY MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 214 LATIN AMERICA: CAR T-CELL THERAPY MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 215 LATIN AMERICA: CAR T-CELL THERAPY MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • TABLE 216 LATIN AMERICA: CAR T-CELL THERAPY MARKET, BY TARGET, 2022–2029 (USD MILLION)
  • TABLE 217 LATIN AMERICA: CAR T-CELL THERAPY MARKET, BY INDICATION, 2022–2029 (USD MILLION)
  • TABLE 218 LATIN AMERICA: CAR T-CELL THERAPY MARKET, BY DEMOGRAPHIC, 2022–2029 (USD MILLION)
  • TABLE 219 LATIN AMERICA: CAR T-CELL THERAPY MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 220 BRAZIL: CAR T-CELL THERAPY MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • TABLE 221 BRAZIL: CAR T-CELL THERAPY MARKET, BY TARGET, 2022–2029 (USD MILLION)
  • TABLE 222 BRAZIL: CAR T-CELL THERAPY MARKET, BY INDICATION, 2022–2029 (USD MILLION)
  • TABLE 223 BRAZIL: CAR T-CELL THERAPY MARKET, BY DEMOGRAPHIC, 2022–2029 (USD MILLION)
  • TABLE 224 BRAZIL: CAR T-CELL THERAPY MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 225 REST OF LATIN AMERICA: CAR T-CELL THERAPY MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • TABLE 226 REST OF LATIN AMERICA: CAR T-CELL THERAPY MARKET, BY TARGET, 2022–2029 (USD MILLION)
  • TABLE 227 REST OF LATIN AMERICA: CAR T-CELL THERAPY MARKET, BY INDICATION, 2022–2029 (USD MILLION)
  • TABLE 228 REST OF LATIN AMERICA: CAR T-CELL THERAPY MARKET, BY DEMOGRAPHIC, 2022–2029 (USD MILLION)
  • TABLE 229 REST OF LATIN AMERICA: CAR T-CELL THERAPY MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 230 MIDDLE EAST & AFRICA: CAR T-CELL THERAPY MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • TABLE 231 MIDDLE EAST & AFRICA: CAR T-CELL THERAPY MARKET, BY TARGET, 2022–2029 (USD MILLION)
  • TABLE 232 MIDDLE EAST & AFRICA: CAR T-CELL THERAPY MARKET, BY INDICATION, 2022–2029 (USD MILLION)
  • TABLE 233 MIDDLE EAST & AFRICA: CAR T-CELL THERAPY MARKET, BY DEMOGRAPHIC, 2022–2029 (USD MILLION)
  • TABLE 234 MIDDLE EAST & AFRICA: CAR T-CELL THERAPY MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 235 OVERVIEW OF STRATEGIES DEPLOYED BY KEY MANUFACTURING COMPANIES
  • TABLE 236 CAR T-CELL THERAPY MARKET: DEGREE OF COMPETITION
  • TABLE 237 CAR T-CELL THERAPY MARKET: PRODUCT FOOTPRINT
  • TABLE 238 CAR T-CELL THERAPY MARKET: TARGET FOOTPRINT
  • TABLE 239 CAR T-CELL THERAPY MARKET: INDICATION FOOTPRINT
  • TABLE 240 CAR T-CELL THERAPY MARKET: REGION FOOTPRINT
  • TABLE 241 CAR T-CELL THERAPY MARKET: DETAILED LIST OF KEY STARTUP/SME PLAYERS
  • TABLE 242 CAR T-CELL THERAPY MARKET: COMPETITIVE BENCHMARKING OF KEY EMERGING PLAYERS/STARTUPS
  • TABLE 243 CAR T-CELL THERAPY MARKET: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021–MARCH 2024
  • TABLE 244 CAR T-CELL THERAPY MARKET: DEALS, JANUARY 2021–MARCH 2024
  • TABLE 245 CAR T-CELL THERAPY MARKET: EXPANSIONS, JANUARY 2021–MARCH 2024
  • TABLE 246 CAR T-CELL THERAPY MARKET: OTHER DEVELOPMENTS, JANUARY 2021–MARCH 2024
  • TABLE 247 BRISTOL-MYERS SQUIBB COMPANY: COMPANY OVERVIEW
  • TABLE 248 BRISTOL-MYERS SQUIBB COMPANY: PRODUCTS OFFERED
  • TABLE 249 BRISTOL-MYERS SQUIBB COMPANY: PRODUCT APPROVALS, JANUARY 2021–MAY 2024
  • TABLE 250 BRISTOL-MYERS SQUIBB COMPANY: DEALS, JANUARY 2021–MAY 2024
  • TABLE 251 GILEAD SCIENCES, INC.: COMPANY OVERVIEW
  • TABLE 252 GILEAD SCIENCES, INC.: PRODUCTS OFFERED
  • TABLE 253 GILEAD SCIENCES, INC.: PRODUCT APPROVALS, JANUARY 2021–MAY 2024
  • TABLE 254 GILEAD SCIENCES, INC.: DEALS, JANUARY 2021–MAY 2024
  • TABLE 255 GILEAD SCIENCES, INC.: OTHER DEVELOPMENTS, JANUARY 2021–MAY 2024
  • TABLE 256 NOVARTIS AG: COMPANY OVERVIEW
  • TABLE 257 NOVARTIS AG: PRODUCTS OFFERED
  • TABLE 258 NOVARTIS AG: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021−MAY 2024
  • TABLE 259 NOVARTIS AG: EXPANSIONS, JANUARY 2021−MAY 2024
  • TABLE 260 NOVARTIS AG: OTHER DEVELOPMENTS, JANUARY 2021−MAY 2024
  • TABLE 261 JOHNSON & JOHNSON: COMPANY OVERVIEW
  • TABLE 262 JOHNSON & JOHNSON: PRODUCTS OFFERED
  • TABLE 263 JOHNSON & JOHNSON: PRODUCT APPROVALS, JANUARY 2021−MAY 2024
  • TABLE 264 JOHNSON & JOHNSON: DEALS, JANUARY 2021−MAY 2024
  • TABLE 265 JW (CAYMAN) THERAPEUTICS CO. LTD.: COMPANY OVERVIEW
  • TABLE 266 JW (CAYMAN) THERAPEUTICS CO. LTD.: PRODUCTS OFFERED
  • TABLE 267 JW (CAYMAN) THERAPEUTICS CO. LTD.: PRODUCT APPROVALS, JANUARY 2021−MAY 2024
  • TABLE 268 JW (CAYMAN) THERAPEUTICS CO. LTD.: DEALS, JANUARY 2021−MAY 2024
  • TABLE 269 IMMUNOADOPTIVE CELL THERAPY PRIVATE LIMITED: COMPANY OVERVIEW
  • TABLE 270 IMMUNOADOPTIVE CELL THERAPY PRIVATE LIMITED: PRODUCTS OFFERED
  • TABLE 271 IMMUNOADOPTIVE CELL THERAPY PRIVATE LIMITED: DEALS, JANUARY 2021−MAY 2024
  • TABLE 272 IMMUNOADOPTIVE CELL THERAPY PRIVATE LIMITED: OTHER DEVELOPMENTS, JANUARY 2021–MAY 2024
  • TABLE 273 CARSGEN THERAPEUTICS HOLDINGS LIMITED: COMPANY OVERVIEW
  • TABLE 274 CARSGEN THERAPEUTICS HOLDINGS LIMITED: PRODUCTS OFFERED
  • TABLE 275 CARSGEN THERAPEUTICS HOLDINGS LIMITED: PRODUCT APPROVALS, JANUARY 2021−MAY 2024
  • TABLE 276 CARSGEN THERAPEUTICS HOLDINGS LIMITED: DEALS, JANUARY 2021−MAY 2024
  • TABLE 277 CARSGEN THERAPEUTICS HOLDINGS LIMITED: EXPANSIONS, JANUARY 2021−MAY 2024
  • TABLE 278 IASO BIOTHERAPEUTICS: COMPANY OVERVIEW
  • TABLE 279 IASO BIOTHERAPEUTICS: PRODUCTS OFFERED
  • TABLE 280 IASO BIOTHERAPEUTICS: PRODUCT APPROVALS, JANUARY 2021−MAY 2024
  • TABLE 281 IASO BIOTHERAPEUTICS: DEALS, JANUARY 2021−MAY 2024
LIST OF FIGURES
 
  • FIGURE 1 CAR T-CELL THERAPY MARKET SEGMENTATION
  • FIGURE 2 CAR T-CELL THERAPY MARKET: REGIONAL SEGMENTATION
  • FIGURE 3 RESEARCH DESIGN
  • FIGURE 4 BREAKDOWN OF PRIMARIES: CAR T-CELL THERAPY MARKET
  • FIGURE 5 CAR T-CELL THERAPY MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2023
  • FIGURE 6 CAR T-CELL THERAPY MARKET SIZE ESTIMATION (PRODUCT-BASED ANALYSIS), 2023
  • FIGURE 7 MARKET SIZE ESTIMATION: COMPANY REVENUE ANALYSIS-BASED ESTIMATION (PRODUCTS), 2023
  • FIGURE 8 ILLUSTRATIVE EXAMPLE OF GILEAD SCIENCES, INC.: REVENUE SHARE ANALYSIS (2023)
  • FIGURE 9 MARKET VALIDATION FROM PRIMARY SOURCES
  • FIGURE 10 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH
  • FIGURE 11 CAR T-CELL THERAPY MARKET: CAGR PROJECTIONS, 2024–2029
  • FIGURE 12 DATA TRIANGULATION METHODOLOGY
  • FIGURE 13 CAR T-CELL THERAPY MARKET, BY PRODUCT, 2024 VS 2029 (USD MILLION)
  • FIGURE 14 CAR T-CELL THERAPY MARKET, BY TARGET, 2024 VS. 2029 (USD MILLION)
  • FIGURE 15 CAR T-CELL THERAPY MARKET, BY DEMOGRAPHIC, 2024 VS. 2029 (USD MILLION)
  • FIGURE 16 CAR T-CELL THERAPY MARKET, BY INDICATION, 2024 VS. 2029 (USD MILLION)
  • FIGURE 17 CAR T-CELL THERAPY MARKET, BY END USER, 2024 VS. 2029 (USD MILLION)
  • FIGURE 18 GEOGRAPHICAL SNAPSHOT OF CAR T-CELL THERAPY MARKET
  • FIGURE 19 GROWING PREVALENCE OF CANCER TO DRIVE MARKET
  • FIGURE 20 US AND YESCARTA COMMANDED LARGEST SHARE IN NORTH AMERICAN CAR T-CELL THERAPY MARKET IN 2023
  • FIGURE 21 YESCARTA HELD HIGHEST GLOBAL MARKET SHARE IN 2023
  • FIGURE 22 HOSPITALS SEGMENT TO GROW AT HIGHEST CAGR DURING STUDY PERIOD
  • FIGURE 23 CAR T-CELL THERAPY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • FIGURE 24 REVENUE SHIFT IN CAR T-CELL THERAPY MARKET
  • FIGURE 25 VALUE CHAIN ANALYSIS: CAR T-CELL THERAPY PRODUCTS
  • FIGURE 26 CAR T-CELL THERAPY MARKET: ECOSYSTEM
  • FIGURE 27 TOTAL NUMBER OF PATENTS GRANTED IN CAR T-CELL THERAPY MARKET, 2014–2023
  • FIGURE 28 TOP 13 PLAYERS WITH HIGHEST NUMBER OF PATENT APPLICATIONS, 2014–2024
  • FIGURE 29 REGIONAL ANALYSIS OF PATENTS GRANTED, 2014–2024
  • FIGURE 30 CAR T-CELL THERAPY MARKET
  • FIGURE 31 KEY STAKEHOLDERS IN PRODUCT BUYING PROCESS
  • FIGURE 32 KEY BUYING CRITERIA FOR PRODUCTS
  • FIGURE 33 NORTH AMERICA: CAR T-CELL THERAPY MARKET SNAPSHOT
  • FIGURE 34 ASIA PACIFIC: CAR T-CELL THERAPY MARKET SNAPSHOT
  • FIGURE 35 REVENUE ANALYSIS OF KEY PLAYERS IN CAR T-CELL THERAPY MARKET (2021–2023)
  • FIGURE 36 MARKET SHARE ANALYSIS OF KEY PLAYERS IN CAR T-CELL THERAPY MARKET (2023)
  • FIGURE 37 RANKING OF KEY PLAYERS IN CAR T-CELL THERAPY MARKET, 2023
  • FIGURE 38 CAR T-CELL THERAPY MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2023
  • FIGURE 39 CAR T-CELL MARKET: COMPANY FOOTPRINT
  • FIGURE 40 CAR T-CELL THERAPY MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2023
  • FIGURE 41 EV/EBITDA OF KEY VENDORS
  • FIGURE 42 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
  • FIGURE 43 CAR T-CELL THERAPY MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS
  • FIGURE 44 BRISTOL-MYERS SQUIBB COMPANY: COMPANY SNAPSHOT (2023)
  • FIGURE 45 GILEAD SCIENCES, INC.: COMPANY SNAPSHOT (2023)
  • FIGURE 46 NOVARTIS AG: COMPANY SNAPSHOT (2023)
  • FIGURE 47 JOHNSON & JOHNSON: COMPANY SNAPSHOT (2023)
  • FIGURE 48 JW (CAYMAN) THERAPEUTICS CO. LTD.: COMPANY SNAPSHOT (2023)

This study involved four major activities in estimating the current size of the CAR T-cell therapy market. Exhaustive secondary research was carried out to collect information on the market, its peer markets, and its parent market. These findings, assumptions, and sizing were then validated with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. Following this, market breakdown and data triangulation procedures were used to estimate the market size of segments and subsegments.

Secondary Research

Secondary research was used mainly to identify and collect information for the extensive, technical, market-oriented, and commercial study. The secondary sources referred for this research study include publications from government sources, such as the National Center for Biotechnology Information (NCBI), National Institutes of Health (NIH), World Health Organization (WHO), United States Food and Drug Administration (US FDA), American Society of Gene & Cell Therapy (ASGCT), European Medicines Agency (EMA), Industry Association of Synthetic Biology (IASB), International Society for Cell & Gene Therapy (ISCT), National Center for Complementary and Integrative Health (NCCIH), BioPharm International, ScienceDirect, News Articles, Journals, Press Releases, Paid Databases, Expert Interviews, and MarketsandMarkets Analysis, among others. Secondary sources also included corporate and regulatory filings (such as annual reports, SEC filings, investor presentations, and financial statements); business magazines and research journals; press releases; and trade, business, and professional associations. These sources were also used to obtain key information about major players, global product revenues, market classification, and segmentation according to industry trends, regional/country-level markets, market developments, and technology perspectives. Secondary data was collected and analyzed to arrive at the overall size of the global CAR T-cell therapy market, which was validated through primary research.

Primary Research

In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, among other experts, to obtain and verify the critical qualitative and quantitative information as well as assess future prospects of the market. Various primary sources from both the supply and demand sides of the market were interviewed to obtain qualitative and quantitative information. The following is a breakdown of the primary respondents:

CAR T-cell therapy Market Size, and Share

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

The global size of the CAR T-cell therapy market was estimated through multiple approaches. A detailed market estimation approach was followed to estimate and validate the value of the market and other dependent submarkets. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

  • The major players in the industry and market have been identified through extensive primary and secondary research.
  • The CAR T-cell therapy-related business shares of leading players have been determined through secondary research and primary analysis.
  • All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources.

Market Size Estimation Methodology-Bottom-up approach

CAR T-cell therapy Market Size, and Share

To know about the assumptions considered for the study, Request for Free Sample Report

Top-down Approach-

CAR T-cell therapy Market Size, and Share

Data Triangulation

After estimating the overall market size from the market size estimation process, the total market was split into several segments. To complete the overall market engineering process and arrive at the exact statistics for all segments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.

Market Definition

CAR T-cell therapy is a treatment method wherein a patient's T-cells (a type of immune system cell) undergo modification in a laboratory to target and attack cancer cells effectively. Initially, T-cells are extracted from the patient's bloodstream. Then the gene for a special receptor that binds to a specific protein on the patient's cancer cells is added to the T cells in the laboratory. The special receptor is known as chimeric antigen receptor (CAR). Following this modification process, the CAR T-cells are cultured and multiplied in large quantities. Finally, the amplified CAR T-cells are administered to the patient via infusion. This therapeutic approach is predominantly utilized in the management of specific blood cancers, and ongoing research is exploring its potential applications in treating other forms of cancer. The CAR T-Cell therapy market includes approved and pipeline CAR T-cell products for therapy purpose.

Key Stakeholders

  • Pharmaceutical Companies
  • Biotechnology Companies
  • Clinical Research Organizations (CROs)
  • Regulatory Authorities
  • Healthcare Providers
  • Patients and Patient Advocacy Groups
  • Investors and Venture Capital Firms
  • Research & Development Companies
  • Research Laboratories & Academic Institutes.
  • Market Research & Consulting Firms

The main objectives of this study are as follows:

  • To define, describe, and forecast the CAR T-cell therapy market by value for product, target, indication, demographic, end user, and region
  • To define, describe, and forecast the CAR T-cell therapy market by volume for the product segment at global level.
  • To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
  • To analyze the micromarkets with respect to individual growth trends, prospects, and contributions to the overall CAR T-cell therapy market
  • To analyze the opportunities for stakeholders and provide details of the competitive landscape for market leaders
  • To forecast the size of the market segments with respect to five regions: North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa
  • To profile the key players and analyze their market shares and core competencies
  • To track and analyze competitive developments, such as product launches, partnerships, agreements, collaborations, and expansions.
  • To benchmark players within the market using the proprietary “Company Evaluation Matrix” framework, which analyzes market players on various parameters within the broad categories of business and product excellence strategy.
  • To provide an overview of the market with specialized analysis such as trends/distruptions impacting customers business, pricing analysis, value/ supply chain analysis, ecosystem analysis, technology analysis, patent analysis, key conferences & events 2024-2025, regulatory landscape, porter’s five forces’ analysis, key stakeholder and buying criteria, and investment and funding scenario 

Available Customizations

With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for this report with additional efforts:

Product Information

  • Country-wise Information:  Analysis for additional countries (up to five)
  • Company Information:  Detailed analysis and profiling of additional key market players across the globe

Previous Versions of this Report

Custom Market Research Services

We Will Customise The Research For You, In Case The Report Listed Above Does Not Meet With Your Requirements

Get 10% Free Customisation

Growth opportunities and latent adjacency in CAR T-cell Therapy Market

+1-888600-6441

Corporate Office Hours

+1-888600-6441

US/Can Toll Free

+44-800-368-9399

UK Office Hours

©2024 Marketsandmarkets Research Private Ltd. All Rights Reserved.

DMCA.com Protection Status